Previous 10 | Next 10 |
JERUSALEM , Dec. 3, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the Company has entered into an Ordinary Shares Purchase Agreement for $10.0 million with Aspire Capital Fund, LLC ("Aspire Capital"), a Chicag...
JERUSALEM , Nov. 13, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that Company management will participate in the Jefferies London Healthcare Conference. Jefferies London Healthcare Conference Date: November 20-21, 2019 ...
Intec Pharma (NASDAQ: NTEC ): Q3 GAAP EPS of -$0.61 misses by $0.39 . More news on: Intec Pharma Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...
JERUSALEM , Nov. 12, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the three and nine months ended September 30, 2019 . Highlights of the third quarter 2019 and recent weeks include: Presented two posters hi...
JERUSALEM , Sept. 25, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that two posters highlighting data from the Company's Phase 3 clinical development program for the Accordion Pill ® Carbidopa/Levodopa (AP-CD/LD), were presented ye...
Gainers: Ovid Therapeutics (NASDAQ: OVID ) +27% . VolitionRx Limited (NYSEMKT: VNRX ) +24% . Cellcom Israel (NYSE: CEL ) +21% . Wheeler Real Estate Investment Trust (NASDAQ: WHLR ) +19% . Fresh Del Monte Produce (NYSE: FDP ) +16% . New Age Beverages Corporation (NASDAQ: NBEV ) ...
Plus Therapeutics (NASDAQ: PSTV ) +99% on BARDA payment . More news on: Plus Therapeutics, Inc., Avadel Pharmaceuticals plc, Arotech Corporation, Stocks on the move, Read more ...
The following slide deck was published by Intec Pharma Ltd. in conjunction with this Read more ...
September 16, 2019 Palm Beach, FL –September 16, 2019 – The global cancer therapy market looks like it will continue trend to continue its growth… worldwide. Cancer therapies are drugs that block the growth and proliferation of cancer, by interfering with spec...
JERUSALEM , Sept. 16, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that two posters in support of the Company's Phase 3 clinical development program for the Accordion Pill™ Carbidopa/Levodopa (AP-CD/LD), will be presented a...
News, Short Squeeze, Breakout and More Instantly...
Intec Pharma Ltd. Company Name:
NTEC Stock Symbol:
NASDAQ Market:
- Chief Scientific Officer Dr. Newman to present initial clinical data that further validates Company’s “Pulse-Prime” hypothesis - Dr. Newman also named Chair of the Summit NEW YORK, June 11, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a...
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that its Chief Medical Officer, Roger Waltzman, M.D., will present an update on ...
Latest data from first and second cohorts support Company’s 'pulse-prime' approach, demonstrating rapid clearance, broad immune activation, and encouraging safety profile Poster Presented at American Society of Clinical Oncology Annual Meeting NEW YORK, June 03, 2024 (GLOBE...